LB-102-011

For adults with a diagnosis of Bipolar I Disorder currently experiencing a Major Depressive Episode (MDE).

The goal of this study is to evaluate the efficacy, safety, and tolerability of LB-102, compared to placebo, in treating depressive symptoms associated with Bipolar I Disorder.

This study is sponsored by LB Pharmaceuticals.

The purpose of this study is to determine if treatment with a single dose of RE104 reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

This study is sponsored by Reunion

This study is designed to evaluate the efficacy of a single dose of 100 µg of MM-120 (D-lysergic acid diethylamide D-tartrate), versus placebo, for the treatment of depression symptoms.

This study is sponsored by Definium Therapeutics

For adults living with Post Traumatic Stress Disorder (PTSD)

The purpose of this study is to assess the efficacy, safety, and tolerability of TSND-201 for the treatment of PTSD symptoms compared to placebo

This study is sponsored by Transcend Therapeutics, Inc.

This is a phase 3 open-label study evaluating the long-term safety and tolerability of the drug NBI-1117568 in the treatment of adults with schizophrenia.

This study is sponsored by Neurocrine Biosciences, Inc.